Trial Profile

Pilot Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 Sep 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine (Primary) ; Vosaroxin (Primary)
Indications Acute myeloid leukaemia
Focus Therapeutic Use

Most Recent Events

22 Aug 2017 Status changed from suspended to discontinued.
24 Aug 2016 Status changed from recruiting to suspended.
01 Dec 2015 Status changed from not yet recruiting to recruiting according to a Sunesis Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com